BTK and Waldenstrom macroglobulinemia: Ibrutinib is a covalent inhibitor of Bruton's tyrosine kinase (BTK) and it is indicated for the treatment of patients with mantle cell lymphoma (MCL), chronic lymphocytic leukemia, small lymphocytic lymphoma, Waldenström's macroglobulinemia and marginal zone lymphoma.